|19/12/24||GEM137||Biosimilar ranibizumab||Same indications as ranibizumab||intra- vetreal||Antibody||Preclinical||Peptide mapping by Mass Spectrometry confirms amino acid sequence identity of GEM137 with ranibizumab. Purified GEM137 is highly similar to ranibizumab by SDS-PAGE. Ligand (rVEGF) biding by GEM137 demonstrated to be similar to ranibizumab by ELISA. Plant-based technology (TGEM036) was applied for production of GEM137.||問合せ|
|19/12/24||GEM136||Biosimilar trastuzumab||Same indications as trastuzumab||i.v.||Antibody||Preclinical||GEM136 N-terminal sequences are identical to trastuzumab. Levels of contaminating proteins, profiles of breakdown products and inhibitory activity to trastuzumab on in vitro growth of hER2 positive breast cancer cell line are similar between GEM136 and trastuzumab. Plant-based technology (TGEM036) was applied for production of GEM136.||問合せ|
|19/12/20||GEM135||Inhibition of proteasome via novel target||Multiple tumors||i.v., i.p. and Oral||Small molecule||Preclinical||Novel target different from that for all the commercially available proteasome inhibitors. Works against many cancer cell lines tested including bortezomib, cisplatin and paclitaxel resistant cell lines. Significant therapeutic window between cancer and normal cells. Favorable toxicity profile. Regressed tumor growth and prolonged survival on syngeneic and xenograft mouse models. Expected to be effective against solid tumors without off target effects and peripheral neuropathy. Two lead compounds are being developed.||問合せ|
|19/12/06||GEM134||Anti-CD147 antibody||Hematological （AML,MM etc） and solid tumors（liver, colon, lung etc）||i.v.||Antibody||Preclinical||Fully human antibody binding to human/ cynomolgus CD147.
Has been shown to be very effective in various types of cancers in vivo xenograft mouse model.
ADCC activity mainly contributes to the anti-tumor effect.
|19/11/29||GEM058||Increase cellular ATP and promote wound healing||Diabetes foot ulcer||Topical||Small molecules||Phase 2 completed||Reducing inflammation of endothelial cells of blood vessels.
Increasing cellular ATP and speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. The arrangement of actin which is essential for cell migration is ATP dependent.
Applicable to all kind of wound and low cost treatment
|19/11/25||GEM133||Myocardial protection by cardiac arrest temporally||Open heart surgery||Intra- coronary infusion||Others
||Launched||GEM133 is a novel warm cardioplegic solution which in mixture with patient's oxygenated blood can produce effective and sustained cardiac arrest by a single dose 400ml. In addition, it has the following advantages; virtually unlimited aortic cross-clamp time, unassisted resumption of the cardiac rhythm, no ischemic and /or reperfusion injury, no need for cardiotonic support in the immediate postopertaive period.||問合せ|
|19/11/15||GEM132||Matrix metalloproteinase-13 (MMP-13) inhibitor||Refer to Note||Intra- articular or Oral||Small molecule
Extremely potent non-hydroxamic acid containing, non-zinc binding inhibitors of MMP-13 have been identified. High selectivity has been shown for this class of inhibitors over other MMPs. Lead inhibitor tested in the monoiodoacetate (MIA) rat model of OA and shown to protect cartilage when injected into the joint. Exhibits good oral bioavailability in the rat.
|19/11/15||GEM131||Matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitor||Refer to Note||Oral||Small molecule
||Close to IND ready *||Indication:
Neuropathic pain and Amyotrophic Lateral Sclerosis (ALS)
Pain: GEM131 can block inflammatory responses at the site of nerve damage and has been shown to be efficacious in 4 different rodent models of neuropathic pain (spinal nerve ligation, chronic constriction injury of the infraorbital nerve, morphine withdrawal and thermal injury).
ALS: Elevated levels of MMP-2 and-9 have been found in the skin and blood of people with ALS. Significantly improved larval locomotion in both the TDP-43 and SOD1 larvae models in Drosophila. Exhibits good oral bioavailability.
*: Final stages of completion of IND enabling studies for both neuropathic pain & ALS
|19/11/15||GEM130||Antiviral||Infections caused by herpes simplex virus in face and lip||Topical||Small molecule
||Launched||· First cold sore product on the market that combines the therapeutic benefits of an antiviral with an innovative transparent bioadhesive film. · When applied to the lesion, generates a transparent film that acts as a bioadhesive sustained matrix release that improves product bioavailability while promotes itching reduction and wound healing.
· Indicated for the topical treatment of symptoms (tingling, burning, discomfort) of recurrent herpes labialis caused by herpes simplex virus (VHS).
|19/11/15||GEM129||Immuno-modulator||Anogenital warts, Actinic keratosis, Basal cell carcinoma||Topical||Small molecule
||Phase 2||· The first product on the market that combines the therapeutic benefits of a marketed immunomodulator with an innovative transparent bioadhesive film.
· When applied to the lesion, generates a transparent bioadhesive film, which acts as a reservoir or matrix release and reduces the local reactions and increases the permanence of the product in the action site. · The results of non-clinical studies demonstrate that GEM129 has a better safety profile with an equivalent efficacy than its reference product. Clinical studies on-going.